These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 624694)

  • 1. In vitro activity and clinical pharmacology of cefamandole in comparison to cephalothin.
    Simon VC; Malerczyk V; Nixdorf F
    J Antimicrob Chemother; 1978 Jan; 4(1):85-90. PubMed ID: 624694
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cefamandel--in-vitro activity and pharmacokinetics].
    Simon C; Nixdorf F
    Med Welt; 1979 Apr; 30(14):527-30. PubMed ID: 431391
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative in-vitro activity of cefamandole, cefoxitin, cefuroxime and cephalothin.
    Brorson JE; Norrby R
    Scand J Infect Dis Suppl; 1978; (13):88-93. PubMed ID: 278150
    [No Abstract]   [Full Text] [Related]  

  • 4. In-vitro activities of cefamandole and cephalothin against 1,881 clinical isolates. A multi-center study.
    Barry AL; Schoenknect FD; Shadomy S; Sherris JC; Thornsberry C; Washington JA; Kammer RB
    Am J Clin Pathol; 1979 Nov; 72(5):858-60. PubMed ID: 506998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience in pharmacology in bone and joint surgery with cefamandole and cephalothin.
    Schurman DJ; Moser K; Hirshman HP; Burton DS
    Scand J Infect Dis Suppl; 1980; suppl 25():49-52. PubMed ID: 6937952
    [No Abstract]   [Full Text] [Related]  

  • 6. Cefuroxime, cefamandole, cefoxitin, and cephalothin in vitro susceptibility tests: reassessment of the "class representative" concept, confirmation of disk interpretive criteria, and proposed quality control guidelines.
    Barry AL; Jones RN; Thornsberry C
    Am J Clin Pathol; 1983 Aug; 80(2):182-9. PubMed ID: 6881092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of cefamandole as compared with cephalothin.
    Fong IW; Ralph ED; Engelking ER; Kirby WM
    Antimicrob Agents Chemother; 1976 Jan; 9(1):65-9. PubMed ID: 1259393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre study of the susceptibility of a variety of bacteria to cephalothin, cefamandole, tobramycin and gentamicin.
    du T Naudé W; van den Ende J; Botha P; Forder A; Hyland J; de Klerk HC; Neiteler BF; Koornhof HJ; Robinson R; Robins-Browne R; Block C; Appelbaum PC; Africa CW; van Rensburg AJ; Jooste PJ; Crewe-Browne H; Fernandez A
    S Afr Med J; 1977 Nov; 52(20):798-800. PubMed ID: 305120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of agar-disc-diffusion tests with minimum inhibitory concentrations of cefonicid (SK&F 75073) and cephalothin.
    Grappel SF; Guarini JR; Actor P; Weisbach JA
    J Antibiot (Tokyo); 1980 Jan; 33(1):85-7. PubMed ID: 7372555
    [No Abstract]   [Full Text] [Related]  

  • 10. The in vitro activity of cefamandole against 3312 bacterial isolates. A Norwegian multicentre study.
    Digranes A; Bjorvatn B
    NIPH Ann; 1980 Dec; 3(2):141-7. PubMed ID: 7219840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cooperative study of bacterial incidence and susceptibility to cefamandole and other antibiotics (author's transl)].
    de Vega JC; Pais JR; del Tánago AG
    Med Clin (Barc); 1980 May; 74(10):387-94. PubMed ID: 7412431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile.
    Ratzan KR; Baker HB; Lauredo I
    Antimicrob Agents Chemother; 1978 Jun; 13(6):985-7. PubMed ID: 677864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpretive criteria for cefamandole and cephalothin disk diffusion susceptibility tests.
    Barry AL; Schoenknecht FD; Shadomy S; Sherris JC; Thornsberry C; Washington JA; Kammer RB
    Antimicrob Agents Chemother; 1979 Jan; 15(1):140-1. PubMed ID: 106770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on drug therapy. IV. Parenteral cephalosporins.
    Dahl SL; Elenbaas J; Hamburger S
    J Am Med Womens Assoc (1972); 1980 Apr; 35(4):99-100, 107-8. PubMed ID: 6246160
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative activity of two newer cephalosporins, cefoxitin, and cephalothin against selected Enterobacteriaceae and correlation with enzymatic resistance mechanisms.
    Vuye A; Pijck J; Van Landuyt HW
    J Antimicrob Chemother; 1979 May; 5(3):293-300. PubMed ID: 314440
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of in vitro antimicrobial activity of cefamandole and cefazolin with cephalothin against over 8,000 clinical bacterial isolates.
    Jones RN; Fuchs PC
    Antimicrob Agents Chemother; 1976 Jun; 9(6):1066-9. PubMed ID: 938021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinico-microbiologic bases for the use of new cephalosporins].
    De Bac C; Mascellino MT; Nuti M
    Minerva Med; 1982 Apr; 73(15):899-903. PubMed ID: 6979006
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro antibacterial activity of a new 1-oxa cephalosporin compound.
    Downs JT; Andriole VT
    Yale J Biol Med; 1980; 53(2):149-59. PubMed ID: 6446810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ["In vitro" activity of cefamandole, cefalotin, cefoxitin and cefuroxim against enterobacteria and Staphylococcus aureus isolated in hospital (author's transl)].
    Thabaut A; Durosoir JL; Saliou P
    Pathol Biol (Paris); 1979 Dec; 27(10):649-54. PubMed ID: 395496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug therapy reviews: antimicrobial spectrum, pharmacology and therapeutic use of cefamandole and cefoxitin.
    Fraser DG
    Am J Hosp Pharm; 1979 Nov; 36(11):1503-8. PubMed ID: 391032
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.